Tarsus Pharmaceuticals, Inc. TARS R2KR3KPHARMA
Company Overview
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.26.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $451.36M (+146.7% YoY); net profit $-66.42M.
- Trailing 12 Months Year-on-year growth — revenue +69.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 69.40% |
Stock Price Performance
| 1 Year: | +36.72% |
| 6 Months: | +18.22% |
| 3 Months: | +22.88% |
| 1 Month: | -2.97% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)47.41 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TARS Tarsus Pharmaceuticals, Inc. R2KR3KPHARMA | 72.08 | -67.36 | $3.37B | 0.00% | -16.64% | -13.68% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,306.69 | 43.95 | $1.16T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 267.61 | 31.05 | $644.91B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.19 | 80.56 | $503.96B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 424.98 | 27.29 | $381.46B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 147.24 | 117.79 | $363.27B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 156.27 | 23.61 | $297.02B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 172.57 | 25.80 | $267.64B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 676.54 | 36.45 | $250.15B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | 0 | 0 | 33.43M | 22.02M | 1.24M | 539.00K | 15.28M | 0 | 2.50M | 0 | 1.87M | 27.61M | 40.81M | 48.12M | 78.33M | 102.66M | 118.70M | 162.05M | 173.91M |
| Operating Income | - | - | -633.00K | -2.12M | -3.26M | -10.14M | 10.71M | 7.28M | -15.71M | -19.52M | -5.22M | -22.91M | -24.95M | -32.82M | -40.94M | -37.68M | -33.30M | -25.16M | -26.28M | -22.18M | -14.53M | -6.12M | -19.91M |
| Net Income | -1.75M | -831.00K | -681.00K | -1.96M | -3.25M | -10.14M | 10.38M | 6.34M | -15.70M | -20.24M | -5.74M | -22.51M | -23.42M | -31.42M | -39.15M | -35.73M | -33.29M | -23.42M | -25.12M | -20.34M | -12.59M | -6.97M | -18.55M |
| Diluted EPS | - | - | - | -0.74 | -1.23 | -3.71 | 0.47 | 0.29 | -0.76 | -0.98 | -0.24 | -0.84 | -0.88 | -1.17 | -1.28 | -1.01 | -0.88 | -0.61 | -0.64 | -0.48 | -0.30 | -0.16 | -0.43 |
| R&D Expense | - | - | 399.00K | 1.51M | 1.74M | 7.99M | 16.26M | 7.20M | 10.21M | 12.08M | 9.60M | 10.91M | 12.36M | 12.55M | 12.11M | 12.07M | 12.32M | 12.13M | 14.41M | 15.59M | 16.28M | 22.35M | 31.01M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 57.03M | 25.82M | 17.45M | 182.95M | 451.36M |
| Operating Income | - | -4.30M | -27.00M | -12.16M | -62.71M | -143.16M | -120.57M | -70.97M |
| Net Income | -1.32M | -4.67M | -26.81M | -13.83M | -62.09M | -135.89M | -115.55M | -66.42M |
| Diluted EPS | - | - | -4.32 | -0.67 | -2.52 | -4.62 | -3.07 | -1.59 |
| R&D Expense | - | 3.16M | 18.83M | 41.71M | 42.62M | 50.31M | 53.39M | 64.32M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 58.32M | 171.97M | 178.91M | 227.86M | 265.49M | 376.99M | 562.16M |
| Total Equity | -44.00K | -1.35M | -6.00M | 165.98M | 166.73M | 192.90M | 196.99M | 224.53M | 343.43M |
| Cash & Equivalents | - | - | 57.95M | 168.13M | 171.33M | 71.66M | 224.95M | 94.82M | 183.64M |
| Long Term Debt | - | - | - | - | 0 | 19.43M | 29.82M | 71.84M | 72.44M |
| Total Liabilities | - | - | 919.00K | 5.99M | 12.18M | 34.96M | 68.50M | 152.46M | 218.73M |
| Current Liabilities | - | - | 819.00K | 5.39M | 11.48M | 15.43M | 36.94M | 80.61M | 135.69M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.67M | -21.14M | 3.75M | -49.03M | -117.49M | -83.03M | -12.45M |
| Investing Cash Flow | -175.00K | -456.00K | -586.00K | -144.63M | 140.60M | -199.19M | -42.12M |
| Financing Cash Flow | 59.45M | 131.77M | 21.00K | 93.99M | 130.18M | 154.66M | 143.39M |
| Capital Expenditure | -175.00K | -456.00K | -586.00K | -506.00K | -1.50M | -1.57M | -9.86M |
| Free Cash Flow | -3.85M | -21.59M | 3.16M | -49.54M | -119.00M | -84.59M | -22.31M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | -21.3% | -242.9% | -820.5% | -65.9% | -15.7% |
| Net Margin % | - | - | - | -24.2% | -240.5% | -778.9% | -63.2% | -14.7% |
| ROE % | 97.4% | 77.8% | -16.2% | -8.3% | -32.2% | -69.0% | -51.5% | -19.3% |
| ROCE % | - | -7.5% | -16.2% | -7.3% | -29.5% | -62.6% | -40.7% | -16.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.79% | 3.86M | $282.11M |
| 2 | Deep Track Capital, Lp | 8.36% | 3.67M | $268.26M |
| 3 | RTW Investments LP | 7.65% | 3.36M | $245.60M |
| 4 | Jupiter Topco LLC | 6.40% | 2.81M | $205.49M |
| 5 | Paradigm Biocapital Advisors LP | 6.33% | 2.78M | $203.07M |
| 6 | Morgan Stanley | 4.16% | 1.83M | $133.67M |
| 7 | Vanguard Capital Management LLC | 4.09% | 1.79M | $131.18M |
| 8 | Jennison Associates LLC | 3.79% | 1.66M | $121.71M |
| 9 | Tang Capital Management, LLC | 3.57% | 1.57M | $114.73M |
| 10 | Millennium Management Llc | 3.25% | 1.43M | $104.41M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TARS
Tarsus Pharmaceuticals (TARS) Stock Looks Reasonable On Sales While Earnings Stay Weak - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPNXhOVXZQVWJvRTBSbk5LOGEtOXk0OHNwNHBsTGhIQzhYT1FDMlM4TzEtSGNZSkl0WjZzT0pTLUxvQjRxSGZtREg3eV9kZGVGZW53ZW5YOUVtcHhXLVpQN3c1cGNEakQ1U2lmS2xFRm9SRHdROGNreTcxbVA4TnZxNXUwQ2YwRGVvelZkcH…
Tarsus Stock: Not Cheap, But XDEMVY Makes The Valuation Work (NASDAQ:TARS) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNZ0lERzlvM0xYby1wR0x1MHhGeTlVZ2diUEJCcnpPbmFkMHBOV0gtY2ktX3MzOTNySmc1eVBfQ1dMR2QyekQtYTFta3ZBeHBZNUJMY3I0WXNXN2tjLW82SDZjUU1wN0xBZU9tRE9CeGhXdkw0Q01Wci13Zk5tekZFa1kydXpnT1BLWFhJZU…
TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxPS1lQZjZ1ZF9tNUZrR3gtYjZ3OGtFbE10R09neUU4Q0p2LWx5OFhLQW9VWGc0SEllRUluTDlxX3c4UU1WMmc1M3V6OGdHTXJKeWNoS3B5RkFCSi05V2VhR0o3bE1QalJOU3Q2VWdNdlE3TUtWNERudkN2YnIyck1JeGZ3NUxrRTlaRGlscT…
TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxOMTExWnRjUTBudVNGdW5SX2E3Z0h6d1U3bEJubC1CUnhGc01DZWl3bllnYVRfbUJidjBUR3JoRnN6eGs3bURwcTdlVWo1VUJVYkJhM1hNN1BBSUJfeDNEWUw5SS1yR0tVUE9sMjNSOWk0R1JZSmp4LW5tcDVPOFJDYTFxbEwtRnh3UkVxdH…
TARS Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1ZRkpTR3FNUm1sa2VjVy10NGpRYUQyM1hHYmt5LVJPejF5Mzc3ZVdqUkoxa25YUEFVM2tQYnd5djlFZXhsX3pSZUtpVElIX0JWUkdXN0ZMYzBmS21IaTJyWUxYU3B5THVCaHN6bjJmazU4bUlKQjBueTBn?oc=5" target="_blank">TAR…
Tarsus to Raise About $125M, Selling Stock at $56 a Share - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxOSG9PdGhNdVFOODRLVHdlSnZETDVmUzRsMDdmemJ5ek5BelpvckM4OFg4eWE2aHk5R1VGeHY5REZISWNnRzctQ1B0R2ptbFdOM1Y1TS1OcjcwbEV2Nldpei05VVpOU0tTOVIwWVVsRFhTUnR1WGpqVGhPdlNGbDh4UE1xNXFfcUtkRTUxNU…
TARS — Frequently Asked Questions
What is the current share price of Tarsus Pharmaceuticals, Inc. (TARS)?
As of 2026-10-22 16:30 PDT, Tarsus Pharmaceuticals, Inc. (TARS) trades at $72.08 on NasdaqGS. Its 52-week range is $49.36 to $90.78.
What is the market capitalisation of TARS?
Tarsus Pharmaceuticals, Inc. (TARS) has a market capitalisation of $3.37B on NasdaqGS.
What is the P/E ratio of TARS?
TARS trades at a trailing price-to-earnings (P/E) ratio of -67.36. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is 9.75.
What is the return on equity (ROE) of TARS?
TARS has a return on equity (ROE) of -13.68%. Its return on capital employed (ROCE) is -16.64%.
Is TARS a good stock to buy?
This page provides a data-driven analysis of Tarsus Pharmaceuticals, Inc. (TARS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.